Trulieve Cannabis Corp’s stock struggles amid market volatility, yet its commitment to medical cannabis for serious illnesses offers a hopeful path to growth.
Trulieve Cannabis Corp: A Quincy‑based holding company delivering medical cannabis products to help patients with serious conditions, trading at $6.88 and a $1.33 billion market cap.
Trulieve Cannabis Corp. is preparing for a crucial Q3 earnings call on November 5, 2025, as investors await clarity on the company’s revenue growth, capital allocation, and regulatory compliance amidst market volatility and a fragile valuation.
Trulieve Cannabis Corp. is a leading player in the medical cannabis industry, operating in the US and offering high-quality products to alleviate symptoms of serious medical conditions, with a strong financial presence and commitment to patient care.
Trulieve Cannabis Corp has expanded its presence in Ohio with a new dispensary and made key leadership changes, including appointing a new board member and Chief Financial Officer, to drive growth and operational efficiency.
Shares of Trulieve Cannabis Corp surged 27% after President Trump hinted at reclassifying marijuana as a less dangerous drug, potentially leading to eased federal restrictions and a major transformation in the industry.
Trulieve Cannabis Corp has reported a strong second-quarter performance, beating earnings expectations and surpassing revenue forecasts, solidifying its position as a leader in the US cannabis market.
Trulieve Cannabis Corp experienced a temporary trading halt on the Canadian Securities Exchange due to a single-stock circuit breaker, lasting approximately five minutes before resuming at 11:35:35 AM ET on August 1, 2025.
Trulieve Cannabis Corp. reported strong Q1 2025 results, exceeding expectations with $298 million in revenue and a 62% gross margin, despite challenges in the cannabis market.